Compare HWKN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | VKTX |
|---|---|---|
| Founded | 1938 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 4.4B |
| IPO Year | 1995 | 2014 |
| Metric | HWKN | VKTX |
|---|---|---|
| Price | $139.60 | $34.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $200.00 | $95.86 |
| AVG Volume (30 Days) | 178.2K | ★ 2.4M |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.91 | N/A |
| Revenue | ★ $1,083,696,000.00 | N/A |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | $6.30 | N/A |
| P/E Ratio | $35.63 | ★ N/A |
| Revenue Growth | ★ 11.21 | N/A |
| 52 Week Low | $117.98 | $22.96 |
| 52 Week High | $186.15 | $43.15 |
| Indicator | HWKN | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 44.70 |
| Support Level | $130.08 | $34.03 |
| Resistance Level | $152.94 | $36.77 |
| Average True Range (ATR) | 5.11 | 2.05 |
| MACD | 0.67 | -0.66 |
| Stochastic Oscillator | 38.85 | 3.75 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The Industrial Solutions segment, provides industrial chemicals, products and services to industries such as industrial manufacturing, chemical processing, electronics, energy, plating, and surface finishing. The water treatment segment, which generates the majority of revenue sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. Food and Health Sciences segment specializes in processing and formulation solutions as well as ingredient distribution to manufacturers in the nutrition, food, pharmaceutical, and agricultural markets.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.